KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Assets: 2011-2025

Historic Assets for Travere Therapeutics (TVTX) over the last 14 years, with Sep 2025 value amounting to $538.6 million.

  • Travere Therapeutics' Assets rose 6.77% to $538.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $538.6 million, marking a year-over-year increase of 6.77%. This contributed to the annual value of $594.1 million for FY2024, which is 24.69% down from last year.
  • As of Q3 2025, Travere Therapeutics' Assets stood at $538.6 million, which was down 3.01% from $555.3 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year Assets high stood at $832.9 million for Q3 2023, and its period low was $504.4 million during Q3 2024.
  • For the 3-year period, Travere Therapeutics' Assets averaged around $647.5 million, with its median value being $594.1 million (2024).
  • Per our database at Business Quant, Travere Therapeutics' Assets surged by 33.33% in 2021 and then crashed by 39.44% in 2024.
  • Over the past 5 years, Travere Therapeutics' Assets (Quarterly) stood at $776.6 million in 2021, then dropped by 13.40% to $672.6 million in 2022, then climbed by 17.30% to $788.9 million in 2023, then declined by 24.69% to $594.1 million in 2024, then rose by 6.77% to $538.6 million in 2025.
  • Its Assets stands at $538.6 million for Q3 2025, versus $555.3 million for Q2 2025 and $548.8 million for Q1 2025.